JP2010531811A - ２−置換イソフラボノイド化合物、医薬及び使用 - Google Patents

２−置換イソフラボノイド化合物、医薬及び使用 Download PDF

Info

Publication number
JP2010531811A
JP2010531811A JP2010513583A JP2010513583A JP2010531811A JP 2010531811 A JP2010531811 A JP 2010531811A JP 2010513583 A JP2010513583 A JP 2010513583A JP 2010513583 A JP2010513583 A JP 2010513583A JP 2010531811 A JP2010531811 A JP 2010531811A
Authority
JP
Japan
Prior art keywords
hydroxy
alkyl
compound according
ene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010513583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531811A5 (enExample
Inventor
エイフェ，エレノア
ヒートン，アンドリュー
ウォーカー，キャサリン
ハズバンド，アラン
Original Assignee
ノボゲン リサーチ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007903531A external-priority patent/AU2007903531A0/en
Application filed by ノボゲン リサーチ ピーティーワイ リミテッド filed Critical ノボゲン リサーチ ピーティーワイ リミテッド
Publication of JP2010531811A publication Critical patent/JP2010531811A/ja
Publication of JP2010531811A5 publication Critical patent/JP2010531811A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010513583A 2007-06-29 2008-06-30 ２−置換イソフラボノイド化合物、医薬及び使用 Pending JP2010531811A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903531A AU2007903531A0 (en) 2007-06-29 2-substituted isoflavonoid compounds, medicaments and uses
PCT/AU2008/000960 WO2009003229A1 (en) 2007-06-29 2008-06-30 2-substituted isoflavonoid compounds, medicaments and uses

Publications (2)

Publication Number Publication Date
JP2010531811A true JP2010531811A (ja) 2010-09-30
JP2010531811A5 JP2010531811A5 (enExample) 2011-09-29

Family

ID=40225642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513583A Pending JP2010531811A (ja) 2007-06-29 2008-06-30 ２−置換イソフラボノイド化合物、医薬及び使用

Country Status (6)

Country Link
US (1) US20110166142A1 (enExample)
EP (1) EP2160385A4 (enExample)
JP (1) JP2010531811A (enExample)
AU (1) AU2008271914A1 (enExample)
CA (1) CA2691201A1 (enExample)
WO (1) WO2009003229A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521657A (ja) * 2012-07-03 2015-07-30 ファーマキング カンパニー リミテッドＰｈａｒｍａｋｉｎｇ Ｃｏ．， Ｌｔｄ． Ｓ−アリル−ｌ−システインを有効成分として含む大腸炎予防または治療用組成物、およびこれを含む医薬製剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695703A (zh) * 2009-08-19 2012-09-26 自由州大学 C-3偶合的双类黄酮和c-3偶合的双类黄酮类似物的合成
WO2011066606A1 (en) * 2009-12-01 2011-06-09 Novogen Research Pty Ltd Pyranoindole compounds and uses thereof
GB201017315D0 (en) * 2010-10-13 2010-11-24 Antoxis Ltd Compound
KR101363472B1 (ko) 2011-03-30 2014-02-17 한국화학연구원 신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 ｐａｒ-1 관련 질환의 예방 또는 치료용 약학적 조성물
EP3939583A1 (en) * 2016-04-06 2022-01-19 Noxopharm Limited Improvements in cancer treatment with isoflavonoids
CA3058500A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Targeted drug delivery
EP3439642A4 (en) 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
JP2019513828A (ja) * 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
CN110128384B (zh) * 2019-06-19 2020-12-25 中国科学技术大学 一种多功能性的一氧化氮给体分子、聚合物及其制备方法和应用
CN111039910A (zh) * 2019-12-31 2020-04-21 云南大学 一种光引发的合成3-芳基黄酮或香豆素类化合物的方法及应用
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
JPN6013019985; ＲＵＦＥＲ，Ｃ．Ｅ．　ｅｔ　ａｌ: 'Ｓｔｒｕｃｔｕｒａｌ　ｅｌｕｃｉｄａｔｉｏｎ　ｏｆ　ｈｙｄｒｏｘｙｌａｔｅｄ　ｍｅｔａｂｏｌｉｔｅｓ　ｏｆ　ｔｈｅ　ｉｓｏｆｌａｖａｎ　ｅｑｕｏｌ　ｂｙ　ｇａｓ　ｃｈｒｏｍａｔｏｇｒａｐｈｙ-ｍａｓｓ' Ｄｒｕｇ　Ｍｅｔａｂ　Ｄｉｓｐｏｓ Ｖｏｌ．３４，　Ｎｏ．１, 2006, ｐ．５１-６０ *
JPN6013019986; ＶＡＮＡＮＧＡＭＵＤＩ，Ａ．　ｅｔ　ａｌ: 'Ｃｙｔｏｔｏｘｉｃ　ｅｆｆｅｃｔ　ｏｆ　２，３-ｄｉｓｕｂｓｔｉｔｕｔｅｄ　ｃｈｒｏｍａｎｏｎｅｓ　ｉｎ　ｈｕｍａｎ　ｃａｎｃｅｒ　ｃｅｌｌ　ｌｉｎｅｓ' Ｉｎｄｉａｎ　Ｊ　Ｅｘｐ　Ｂｉｏｌ Ｖｏｌ．３７，　Ｎｏ．２, 1999, ｐ．１７３-５ *
JPN6013019987; Ｈａｊｅｌａ　Ｋ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｐｏｓｔ-ｃｏｉｔａｌ　ｃｏｎｔｒａｃｅｐｔｉｖｅ　ａｃｔｉｖｉｔｙ　ｏｆ　ａ　ｎｅｗ　ｓｅｒｉｅｓ　ｏｆ　ｓｕｂｓｔｉｔｕｔｅｄ　２，３-ｄｉａｒｙｌ-２Ｈ-１-ｂｅｎｚ' Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ ３２（２）, 1997, １３５-４２ *
JPN6013019988; ＳＨＡＲＭＡ，Ａ．Ｐ．　ｅｔ　ａｌ: 'Ｓｔｒｕｃｔｕｒｅ-ａｃｔｉｖｉｔｙ　ｒｅｌａｔｉｏｎｓｈｉｐ　ｏｆ　ａｎｔｉｅｓｔｒｏｇｅｎｓ．　Ｐｈｅｎｏｌｉｃ　ａｎａｌｏｇｕｅｓ　ｏｆ　２，３-ｄｉａｒｙｌ-２Ｈ-１-ｂｅｎｚｏｐｙｒａｎｓ' Ｊ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．３３，　Ｎｏ．１２, 1990, ｐ．３２２２-９ *
JPN6013019989; Ａｆｏｎｙａ　Ｔｈｅｏｐｈｉｌｕｓ　Ｃ．　Ａ　ｅｔ　ａｌ: 'Ｔｈｅ　ｃｈｅｍｉｓｔｒｙ　ｏｆ　ｔｈｅ　'ｉｎｓｏｌｕｂｌｅ　ｒｅｄ　ｗｏｏｄｓ'．　Ｐａｒｔ　１６．　Ｓｏｍｅ　ｆｕｒｔｈｅｒ　ｏｂｓｅｒｖａｔｉｏｎｓ　ｏｎ　ｔｈｅ　ｃｏｎｄｅｎｓａｔｉｏｎ　ｏ' Ｊ．　Ｃｈｅｍ．　Ｒｅｓ． （１０）, 1985, （Ｓ）３０５ *
JPN6013019990; Ｌｉｅｐａ　Ａｎｄｒｉｓ: 'Ａ　Ｓｙｎｔｈｅｓｉｓ　ｏｆ　Ｈｙｄｒｏｘｙｌａｔｅｄ　Ｉｓｏｆｌａｖｙｌｉｕｍ　Ｓａｌｔｓ　ａｎｄ　Ｔｈｅｉｒ　Ｒｅｄｕｃｔｉｏｎ　Ｐｒｏｄｕｃｔｓ' Ａｕｓｔｒａｌｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｅｍｉｓｔｒｙ ３４, 1981, ２６４７-２６５５ *
JPN6013019991; Ｋｏｌｅ，　Ｐ．Ｌ．　ｅｔ　ａｌ: 'Ｓｔｕｄｉｅｓ　ｉｎ　ａｎｔｉｆｅｒｔｉｌｉｔｙ　ａｇｅｎｔｓ　：　Ｐａｒｔ　ＸＸ-２，３-ｃｉｓ-３，４-ｃｉｓ-＆　２，３-ｔｒａｎｓ-３，　４-ｔｒａｎｓ-２-Ｍｅｔｈｙｌ-３-ｐｈｅｎｙｌ-４' Ｉｎｄｉａｎ　Ｊ．　Ｃｈｅｍ． １６Ｂ（８）, 1978, ７２２-２３ *
JPN6013019992; ＤＵＤＬＥＹ，Ｋ．Ｈ．　ｅｔ　ａｌ: 'Ｆｌａｖｏｎｏｉｄｓ．　ＩＶ．　Ａ　ｎｏｖｅｌ　Ｃｌｅｍｍｅｎｓｅｎ　ｒｅｄｕｃｔｉｏｎ．　Ｔｈｅ　ｄｉｒｅｃｔ　ｃｏｎｖｅｒｓｉｏｎ　ｏｆ　２-ａｌｋｙｌｉｓｏｆｌａｖｏｎｅｓ　ｔｏ　２-ａｌｋｙｌ' Ｊ　Ｏｒｇ　Ｃｈｅｍ Ｖｏｌ．３２，　Ｎｏ．７, 1967, ｐ．２３１７-２１ *
JPN6013019993; ＳＨＡＲＭＡ，Ａ．Ｐ．　ｅｔ　ａｌ: 'Ｓｔｒｕｃｔｕｒｅ-ａｃｔｉｖｉｔｙ　ｒｅｌａｔｉｏｎｓｈｉｐ　ｏｆ　ａｎｔｉｅｓｔｒｏｇｅｎｓ．　Ｅｆｆｅｃｔ　ｏｆ　ｔｈｅ　ｓｉｄｅ　ｃｈａｉｎ　ａｎｄ　ｉｔｓ　ｐｏｓｉｔｉｏｎ　ｏｎ　ｔｈｅ　ａ' Ｊ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．３３，　Ｎｏ．１２, 1990, ｐ．３２１６-２２ *
JPN6013019994; ＤＩＪＳＳＥＬＢＬＯＥＭ，Ｎ．　ｅｔ　ａｌ: 'Ｓｏｙ　ｉｓｏｆｌａｖｏｎｅ　ｐｈｙｔｏ-ｐｈａｒｍａｃｅｕｔｉｃａｌｓ　ｉｎ　ｉｎｔｅｒｌｅｕｋｉｎ-６　ａｆｆｅｃｔｉｏｎｓ．　Ｍｕｌｔｉ-ｐｕｒｐｏｓｅ　ｎｕｔｒａｃｅｕｔｉｃａｌｓ　ａｔ　ｔｈ' Ｂｉｏｃｈｅｍ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．６８，　Ｎｏ．６, 2004, ｐ．１１７１-８５ *
JPN6013019995; ＶＡＹＡ，Ｊ．　ｅｔ　ａｌ: 'Ａｎｔｉｏｘｉｄａｎｔ　ｃｏｎｓｔｉｔｕｅｎｔｓ　ｆｒｏｍ　ｌｉｃｏｒｉｃｅ　ｒｏｏｔｓ：　ｉｓｏｌａｔｉｏｎ，　ｓｔｒｕｃｔｕｒｅ　ｅｌｕｃｉｄａｔｉｏｎ　ａｎｄ　ａｎｔｉｏｘｉｄａｔｉｖｅ　ｃａｐ' Ｆｒｅｅ　Ｒａｄｉｃ　Ｂｉｏｌ　Ｍｅｄ Ｖｏｌ．２３，　Ｎｏ．２, 1997, ｐ．３０２-１３ *
JPN6013019996; Ｍａｙｅｒ，　Ｗａｌｔｅｒ　ｅｔ　ａｌ．: 'Ｄｉｅ　Ｒｅａｋｔｉｏｎ　ｄｅｒ　Ｃａｔｅｃｈｉｎｅ　ｍｉｔ　Ｐｈｌｏｒｏｇｌｕｃｉｎ' Ｊｕｓｔｕｓ　Ｌｉｅｂｉｇｓ　Ａｎｎａｌｅｎ　ｄｅｒ　Ｃｈｅｍｉｅ ６４４, 1961, ７０-７８ *
JPN6013019997; Ｃｌａｒｋ-Ｌｅｗｉｓ　］Ｗ．: 'Ｆｌａｖａｎ　ｄｅｒｉｖａｔｉｖｅｓ．　ＸＸＩ．　Ｎｕｃｌｅａｒ　ｍａｇｎｅｔｉｃ　ｒｅｓｏｎａｎｃｅ　ｓｐｅｃｔｒａ，　ｃｏｎｆｉｇｕｒａｔｉｏｎ，　ａｎｄ　ｃｏｎｆｏｍｉａｔｉｏｎ　ｏｆ　ｆｌａｖ' ＡｕｓｔＪ．Ｃｈｅｒｎ． ２１, 1968, ２０５９-７５ *
JPN6013019998; Ｒａｌｐｈ　Ｍｏｚｉｎｇｏ，　ｅｔ　ａｌ．: 'Ｈｙｄｒｏｇｅｎａｔｉｏｎ　ｏｆ　Ｐｙｒｏｎｅｓ' Ｊ．　Ａｍ．　Ｃｈｅｍ．　Ｓｏｃ． ６０　（３）, 1938, ６６９-７５ *
JPN6013019999; ＭＩＤＤＬＥＴＯＮ，Ｅ．: 'Ｅｆｆｅｃｔ　ｏｆ　ｐｌａｎｔ　ｆｌａｖｏｎｏｉｄｓ　ｏｎ　ｉｍｍｕｎｅ　ａｎｄ　ｉｎｆｌａｍｍａｔｏｒｙ　ｃｅｌｌ　ｆｕｎｃｔｉｏｎ' Ａｄｖ　Ｅｘｐ　Ｍｅｄ　Ｂｉｏｌ Ｖｏｌ．４３９, 1998, ｐ．１７５-８２ *
JPN6013020000; Ｊａｍｅｓ　Ｏ．　ｅｔ　ａｌ．: 'Ｔｈｅ　ｃｈｅｍｉｓｔｒｙ　ｏｆ　ｔｈｅ　ｉｎｓｏｌｕｂｌｅ　ｒｅｄ　ｗｏｏｄｓ．　Ｐａｒｔ　１３．　Ｓｙｎｔｈｅｓｉｓ　ｏｆ　２-（ｆｌａｖａｎ-３-ｙｌ）ｉｓｏｆｌａｖ-３-ｅｎｅｓ　ａｎｄ　ｏｆ' Ｊ．　Ｃｈｅｍ．　Ｓｏｃ．，　Ｐｅｒｋｉｎ　Ｔｒａｎｓ．　１ １, 1978, ８８-９２ *
JPN6013020002; ＧＵＰＴＡ　Ｄ．Ｒ．　ＥＴ　ＡＬ: 'Ｃｏｎｄｅｎｓａｔｉｏｎ　ｐｒｏｄｕｃｔｓ　ｏｆ　ｄｅｈｙｄｒｏａｃｅｔｉｃ　ａｃｉｄ　ｗｉｔｈ　ｓｏｍｅ　ｐｒｉｍａｒｙ　ａｍｉｎｅｓ' Ｊ．　ＩＮＤＩＡＮ　ＣＨＥＭ．　ＳＯＣ． ｖｏｌ．　４２，　ｎｏ．　１２, 1965, ８７３-４ *
JPN6013020004; ＪＷ　Ｃｌａｒｋ-Ｌｅｗｉｓ　ｅｔ　ａｌ．: 'Ｔｈｅ　ａｂｓｏｌｕｔｅ　ｃｏｎｆｉｇｕｒａｔｉｏｎｓ　ｏｆ　ｓｏｍｅ　１，２-ｄｉａｒｙｌｐｒｏｐａｎｅ　ｄｅｒｉｖａｔｉｖｅｓ　ａｎｄ　ｏｆ　ｓｏｍｅ　ｉｓｏｆｌａｖａｎｓ' Ａｕｓｔｒａｌｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｅｍｉｓｔｒｙ １８（７）, 1965, １０３５-４８ *
JPN6013020007; Ｃｌａｒｋ-Ｌｅｗｉｓ　ｅｔ　ａｌ．: 'Ｆｌａｖａｎ　ｄｅｒｉｖａｔｉｖｅｓ．　ＶＩ．　Ｔｈｅ　ａｂｓｏｌｕｔｅ　ｃｏｎｆｉｇｕｒａｔｉｏｎｓ　ｏｆ　ｓｏｍｅ　ｆｌａｖａｎ-３，４-ｄｉｏｌ　ｌｅｕｃｏａｎｔｈｏｃｙａｎｉｄｉｎｓ：　（-）' Ｊ．Ｃｈｅｍ．Ｓｏｃ． , 1962, ４５０２-８ *
JPN7013001550; Ｇ　Ｄｏｍｓｃｈｋｅ: '３-Ａｍｉｎｏ-６-ｈｙｄｒｏｘｙ-４-ａｔｈｏｘｙｃａｒｂｏｎｙｌ-ｃｕｍａｒｉｎ　ｕｎｄ　Ｆｏｌｇｅｐｒｏｄｕｋｔｅ' Ｃｈｅｍｉｓｅｈｅ　Ｂｅｒｉｃｈｔｃ　Ｊａｈｒｇ． ９, 1965, ２９２０-５ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521657A (ja) * 2012-07-03 2015-07-30 ファーマキング カンパニー リミテッドＰｈａｒｍａｋｉｎｇ Ｃｏ．， Ｌｔｄ． Ｓ−アリル−ｌ−システインを有効成分として含む大腸炎予防または治療用組成物、およびこれを含む医薬製剤

Also Published As

Publication number Publication date
EP2160385A4 (en) 2010-10-27
EP2160385A1 (en) 2010-03-10
AU2008271914A1 (en) 2009-01-08
US20110166142A1 (en) 2011-07-07
WO2009003229A1 (en) 2009-01-08
CA2691201A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
JP2010531811A (ja) ２−置換イソフラボノイド化合物、医薬及び使用
US8163795B2 (en) Chroman derivatives, medicaments and use in therapy
NZ539034A (en) Aminated isoflavonoid derivatives and uses thereof
JP7181565B2 (ja) Ｙａｐ－ｔｅａｄ結合を阻害する化合物、およびそれを有効成分として含有する癌の予防または治療用医薬組成物
AU2020271268A1 (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
EP1809618B1 (en) Chroman derivatives, medicaments and use in therapy
AU2002333626B2 (en) 1-glyoxlylamide indolizines for treating cancer
JP2008537545A (ja) イソフラボノイド二量体
CN101094844A (zh) 苯并二氢吡喃衍生物，药物及其在治疗中的应用
CN114616234B (zh) 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
JP4913056B2 (ja) 置換クロマン誘導体、医薬品、および治療における使用
CA3209386A1 (en) Flavone deaza spermidine analogues and their use treating cancer
AU2013309723A1 (en) N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug
AU2005201855B2 (en) Chroman derived compounds and formulations thereof for use in therapy
CN114907189A (zh) 多酚取代的3-芳基-2-芳基甲基丙烯类化合物及其制备方法和应用
CN114907193A (zh) 一种基于Claisen重排反应的多酚类化合物及其制备方法和应用
CN117285523A (zh) 一种芹菜素衍生物及其在抗肿瘤中的应用
CA2506238C (en) Chroman derived compounds & formulations thereof for use in therapy
CN112661738A (zh) 二氢黄酮类化合物及其制备方法和应用
WO2023274203A1 (zh) 一种含氮多环类芳香化合物及其制备方法和应用
CN114907190A (zh) 一种基于间位取代苯酚的多酚类化合物及制备方法和应用
IL182042A (en) Chroman derivatives, medicaments and use in therapy
HK1112617B (en) Chroman derivatives, medicaments and use in therapy
HK1108685B (en) Substituted chroman derivatives, medicaments and use in therapy
HK1108685A1 (en) Substituted chroman derivatives, medicaments and use in therapy

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20100209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131015